he uptake of genomic-based innovations can be affected by various social, economic and environmental factors, including legal and regulatory requirements, especially when they represent significant changes to current practices. Already, research into the implications of genomics in society (GE3LS research) conducted through Large-Scale Applied Research Projects (LSARPs) helps better understand these factors primarily in the context of individual projects, but also in relation to sectors. However, to ensure the effective and responsible translation of innovative genomic applications, Genome Canada has developed a Genomics in Society Interdisciplinary Research Teams Program to facilitate collaborations and dialogue between researchers and other key stakeholders whose sectors stand to be transformed by genomics advances.
This funding opportunity builds on the complementary mandates of Genome Canada and AAFC and provides an opportunity to bring together and maximize the effectiveness of the research communities, infrastructure, and resources supported by both organizations. This funding opportunity makes it possible to collaboratively carry out joint projects with AAFC researchers, where Genome Canada funds will support the Genome Canada eligible researchers and AAFC funds will support the AAFC researchers.
Genome Canada has launched a national initiative for the clinical implementation of precision health, focusing on a rare disease pilot program as a foundational step.In order to initiate this ambitious program, Genome Canada is encouraging the submission of projects to the Genomic Applications Partnership Program (GAPP) that will translate research into clinical implementation with the goal of having genome sequencing offered as a clinical genetic test within an established diagnostic and clinical care pathway for rare diseases. The other activities in the Precision Health Initiative – Rare Diseases will be advanced through other funding mechanisms.
The Genomic Applications Partnership Program will fund downstream research and development (R&D) projects that address real world challenges and opportunities as identified by users of genomics research (i.e. industry, government, not-for-profits and other organizations). Downstream R&D includes proof of concept, validation or development of a product, tool or process having significant commercial market potential, or other measurable impact.
Who can I contact if I have a project enquiry?
Simon Potter, Chief Scientific Officer
Shawna Bieber, Program Manager